Verition Fund Management
NMRA icon

Verition Fund Management’s Neumora Therapeutics NMRA Stock Holding History

Verition Fund Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-101,790
Closed -$74.6K – 3927
2025
Q2 		$74.6K Sell
101,790
-169,573
-62% -$128K ﹤0.01% 3507
2025
Q1 		$271K Buy
+271,363
New +$465K ﹤0.01% 2905
2024
Q3 		– Sell
-25,756
Closed -$253K – 3419
2024
Q2 		$253K Buy
25,756
+3,730
+17% +$38.6K ﹤0.01% 2450
2024
Q1 		$303K Buy
+22,026
New +$356K ﹤0.01% 2295

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Verition Fund Management's NMRA Position: Q3 2025 in Review

Verition Fund Management sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 101,790 shares — an estimated $74.6K sold.

Verition Fund Management first reported a position in NMRA in Q1 2024 and held it in 4 quarters. The position peaked at $303K in Q1 2024. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Verition Fund Management reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 101,790 Neumora Therapeutics shares in Q3 2025, an estimated $74.6K.
  • Verition Fund Management first reported a position in Neumora Therapeutics in Q1 2024 and held it in 4 quarters.
  • Verition Fund Management's Neumora Therapeutics position peaked at $303K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.